© SYMYOO Inc. All rights reserved.
Symyoo participated in Korea CDISC Coordinating Committee (K3C) and achieved CDISC/SCDM industry partnership, which is granted to a company having comprehensive data management capability for clinical research.
Symyoo EDC system, SYNeRA™, expanded its functionalities by integrating new modules, including IWRS (Interactive Web-based Randomization System), IP Accountability (Investigational Product Tracking and Management System), and RBM (Risk-Based Monitoring System). Symyoo IWRS can handle various randomization algorithms from simple permuted block randomization to very complex covariate adaptive randomization (biased coin, minimum sufficient).
Conducted more than 150 clinical studies, including 30 oncology trials over 9 years since its foundation in 2009. Symyoo had been coordinating and collaborating with various
Launched Symyoo EDC system, SYNeRA™ for clinical research data collection and management. Symyoo SMART TRIALS research center continues to develop and expand SYNeRA™ functionalities into a web-based Comprehensive Clinical Trial Management System.
Began research collaboration with Global Clinical Trial Center of Anam Hospital, Korea University Medical Center
Qualified for full membership in Korea Clinical Trial CRO Association.
Established SMART TRIALS center to research and facilitate new IT technologies for tomorrow’s medicines. Symyoo reorganized data management and biostatistics team to offer broader data management services.
Partnership contract with Clinical Trial Center of Baek University Hospital, Inje University
Symyoo was designated as the Korea coordinating center to run a multinational phase III clinical trial, which was the first NIH/NINDS study (ATACH 2: Antihypertensive Treatment of Acute Cerebral Hemorrhage II) operated in South Korea. The sponsor audit was also conducted to evaluate trial conduct and compliance with the protocol and SOPs without finding any … First Global Phase III Trial As Coordinating Center
Symyoo expanded its business into a full scope CRO and began to operate a first phase III trial for premature ejaculation study.